182 related articles for article (PubMed ID: 20850369)
1. A comparative study of Lrrk2 function in primary neuronal cultures.
Dächsel JC; Behrouz B; Yue M; Beevers JE; Melrose HL; Farrer MJ
Parkinsonism Relat Disord; 2010 Dec; 16(10):650-5. PubMed ID: 20850369
[TBL] [Abstract][Full Text] [Related]
2. Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.
Winner B; Melrose HL; Zhao C; Hinkle KM; Yue M; Kent C; Braithwaite AT; Ogholikhan S; Aigner R; Winkler J; Farrer MJ; Gage FH
Neurobiol Dis; 2011 Mar; 41(3):706-16. PubMed ID: 21168496
[TBL] [Abstract][Full Text] [Related]
3. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
[TBL] [Abstract][Full Text] [Related]
4. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4.
Häbig K; Gellhaar S; Heim B; Djuric V; Giesert F; Wurst W; Walter C; Hentrich T; Riess O; Bonin M
Biochim Biophys Acta; 2013 Dec; 1832(12):2352-67. PubMed ID: 24075941
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated Wnt and NFAT signaling in a Parkinson's disease LRRK2 G2019S knock-in model.
Wetzel A; Lei SH; Liu T; Hughes MP; Peng Y; McKay T; Waddington SN; Grannò S; Rahim AA; Harvey K
Sci Rep; 2024 May; 14(1):12393. PubMed ID: 38811759
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
[TBL] [Abstract][Full Text] [Related]
8. Short- and long-term effects of LRRK2 on axon and dendrite growth.
Sepulveda B; Mesias R; Li X; Yue Z; Benson DL
PLoS One; 2013; 8(4):e61986. PubMed ID: 23646112
[TBL] [Abstract][Full Text] [Related]
9. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
Plowey ED; Cherra SJ; Liu YJ; Chu CT
J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054
[TBL] [Abstract][Full Text] [Related]
10. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.
West AB; Cowell RM; Daher JP; Moehle MS; Hinkle KM; Melrose HL; Standaert DG; Volpicelli-Daley LA
J Comp Neurol; 2014 Aug; 522(11):2465-80. PubMed ID: 24633735
[TBL] [Abstract][Full Text] [Related]
11. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
[TBL] [Abstract][Full Text] [Related]
12. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
Yue M; Hinkle KM; Davies P; Trushina E; Fiesel FC; Christenson TA; Schroeder AS; Zhang L; Bowles E; Behrouz B; Lincoln SJ; Beevers JE; Milnerwood AJ; Kurti A; McLean PJ; Fryer JD; Springer W; Dickson DW; Farrer MJ; Melrose HL
Neurobiol Dis; 2015 Jun; 78():172-95. PubMed ID: 25836420
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
Luerman GC; Nguyen C; Samaroo H; Loos P; Xi H; Hurtado-Lorenzo A; Needle E; Stephen Noell G; Galatsis P; Dunlop J; Geoghegan KF; Hirst WD
J Neurochem; 2014 Feb; 128(4):561-76. PubMed ID: 24117733
[TBL] [Abstract][Full Text] [Related]
14. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
15. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.
Melrose HL; Dächsel JC; Behrouz B; Lincoln SJ; Yue M; Hinkle KM; Kent CB; Korvatska E; Taylor JP; Witten L; Liang YQ; Beevers JE; Boules M; Dugger BN; Serna VA; Gaukhman A; Yu X; Castanedes-Casey M; Braithwaite AT; Ogholikhan S; Yu N; Bass D; Tyndall G; Schellenberg GD; Dickson DW; Janus C; Farrer MJ
Neurobiol Dis; 2010 Dec; 40(3):503-17. PubMed ID: 20659558
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis.
Parisiadou L; Xie C; Cho HJ; Lin X; Gu XL; Long CX; Lobbestael E; Baekelandt V; Taymans JM; Sun L; Cai H
J Neurosci; 2009 Nov; 29(44):13971-80. PubMed ID: 19890007
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.
Melrose HL; Kent CB; Taylor JP; Dachsel JC; Hinkle KM; Lincoln SJ; Mok SS; Culvenor JG; Masters CL; Tyndall GM; Bass DI; Ahmed Z; Andorfer CA; Ross OA; Wszolek ZK; Delldonne A; Dickson DW; Farrer MJ
Neuroscience; 2007 Jul; 147(4):1047-58. PubMed ID: 17611037
[TBL] [Abstract][Full Text] [Related]
19. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
20. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice.
Beccano-Kelly DA; Kuhlmann N; Tatarnikov I; Volta M; Munsie LN; Chou P; Cao LP; Han H; Tapia L; Farrer MJ; Milnerwood AJ
Front Cell Neurosci; 2014; 8():301. PubMed ID: 25309331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
